Roth Capital Downgrades Warner Chilcott (WCRX) to Hold
More News related to WCRX
- Warner Chilcott to Present at the 27th Annual JP Morgan Healthcare Conference
- Warner Chilcott (WCRX) Signs Agreement with Dong-A PharmTech to Develop and Market Erectile Dysfunction Treatment
- Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
- Warner Chilcott to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
- Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Roth Capital downgrades Warner Chilcott (Nasdaq: WCRX) from Buy to Hold with an $18 price target.
Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women's healthcare and dermatology segments in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
